The importance of glial cells in the modulation of neuronal processes is now generally accepted. In 26 particular, enormous progress in our understanding of astrocytes and microglia physiology in the 27 central nervous system (CNS) has been made in recent years, due to the development of genetic and 28 molecular toolkits. However, the roles of satellite glial cells (SGCs) and macrophagesthe peripheral 29 counterparts of astrocytes and microgliaremain poorly studied despite their involvement in 30 debilitating conditions, such as pain. Here, we characterized in dorsal root ganglia (DRGs), different 31 genetically-modified mouse lines previously used for studying astrocytes and microglia, with the goal 32 to implement them for investigating DRG SGC and macrophage functions. Although SGCs and 33 astrocytes share some molecular properties, most tested transgenic lines were found to not be suitable 34
Introduction 51
Astrocytes and microglia serve essential support and immune functions, and contribute to diseases of 52 the CNS (1). For a long time, their heterogeneity and roles in the CNS have remained unclear due to 53 the lack of tools to specifically identify them, and monitor or alter their activity. However, over the 54 last fifteen years, new genetically-encoded tools to selectively visualize astrocytes and microglia as 55 well as read out or abolish astrocytic Ca 2+ activity have been generated. They include (i) transgenic 56 mice expressing green fluorescent protein (GFP) under the control of astrocytic or microglial 57 promoters (2-5), (ii) transgenic mice expressing genetically-encoded Ca 2+ indicators (GCaMP) to 58 monitor astrocyte Ca 2+ dynamics (6-8), or (iii) IP 3 R2 knockout mice to abolish global G q protein-59 coupled receptor (G q GPCR)-mediated Ca 2+ elevations in astrocyte cell bodies and large processes 60 (9,10). These tools have been extremely useful for probing astrocyte and microglia functions in the 61 CNS and are now extensively used in the field. 62
In the peripheral nervous system (PNS), SGCs in DRGs share several properties with astrocytes, 63
including expression of cytosolic proteins [e.g. glial fibrillary acidic protein: GFAP (11); S100 64 calcium-binding protein beta: S100 (12); glutamine synthetase (13)], membrane neurotransmitter 65 transporters [e.g. glutamate aspartate transporter: GLAST (13) ], and channels [e.g. inwardly rectifying 66 K + channel 4.1 (Kir 4.1) (14); connexin 43 (Cx43)-based gap junctions and hemichannels (15)]. As 67 astrocytes and many other cell types, SGCs use Ca 2+ as a signaling molecule (16) . Additionally, there 68 is substantial evidence for a SGC role in chronic pain wherein SGCs undergo a reactive gliotic 69 response accompanied with increased GFAP expression, hypertrophy, proliferation and upregulation 70 of Cx43 (17, 18) . Furthermore, the counterparts of CNS microglia in DRGs are the macrophages, and 71 both express the ionized Ca 2+ -binding adapter molecule 1 (Iba1) (19, 20) . Emerging evidence has 72 implicated the contribution of DRG macrophages to neuropathic pain development and axonal repair 73 in the context of nerve injury (21-23). Thus, understanding how SGC and macrophage morphology 74 and function are remodeled in physiology and pathology can help to find new therapeutic targets for 75 pain-related diseases (13, (24) (25) (26) . However, SGC and macrophage heterogeneity and role remain 76 largely unknown in DRGs, mainly due to the unavailability of tools to specifically visualize DRG glial 77 6 Calcium imaging. Acute intact DRG preparations were prepared from GFAP-Cre::GCaMP6f mice. 129
Briefly, vertebras and dura mater were removed and lumbar L4 and L5 DRGs were exposed and 130 immediately covered with ice cold (slushy) incubation ACSF solution (95 mM NaCl, 1.9 mM KCl, 1.2 131 mM KH 2 PO 4 , 0.5 mM CaCl 2 , 7 mM MgSO 4 , 26 mM NaHCO 3 , 15 mM glucose, 50 mM sucrose) and 132 bubbled with 95% O 2 and 5% CO 2 . DRGs were incubated for 30 min at 35°C in the incubation 133 solution and then left to recover for 1 h 30 min at room temperature. A single DRG was placed in the 134 recording chamber of a custom-built 2-photon laser-scanning microscope with a 20x water immersion 135 objective (x20/0.95w XLMPlanFluor, Olympus). GCaMP6f was excited at 920 nm with a Ti:Sapphire 136 laser (Mai Tai HP; Spectra-Physics). DRGs were continuously superfused at a rate of 4 ml/min with 137 recording solution (127 mM NaCl, 1.9 mM KCl, 1.2 mM KH 2 PO 4 , 2.4 mM CaCl 2 , 1.3 mM MgSO 4 , 26 138 mM NaHCO 3 , 15 mM glucose) and bubbled with 95% O2 -5% CO2. To evoke intracellular Ca 2+ 139 elevations in DRG GCaMP6f-expressing cells, a cocktail of agonists to endogenous G q GPCRs 140 containing 50 µM DHPG (Abcam), 10 µM histamine (Sigma Aldrich), 10 µM carbachol (Abcam), and 141 50 µM ATP (Sigma Aldrich) was bath applied for 30 sec. 
Results

145
TRANSGENIC MOUSE LINES FOR INVESTIGATING THE DISTRIBUTION AND MORPHOLOGY OF SGCs
146
AND MACROPHAGES
147 S100β-eGFP mice exhibit eGFP expression in both SGCs and sensory neurons. S100 protein is a 148 commonly used astrocytic marker in the brain and spinal cord and has also been reported to be a 149 marker of SGCs in DRGs (12, 32) . The S100β-eGFP transgenic mouse (5), which expresses enhanced 150 GFP (eGFP) under the control of the S100β promoter, has proved to be a useful tool to selectively 151 label almost all astrocytes (32, 33) . In the primary visual cortex (V1), we found that eGFP was 152 expressed in 86% of astrocytes ( Fig 1A; Table 2 ) and only marginally (0.02%) in neurons (Fig 1B;  153 Table 2), corroborating those previous studies. This mouse line appears also to be valuable for 154 labeling SGCs within DRGs, since eGFP immunoreactivity was detected in 85.8% of SGCs as shown 7 by the colocalization of eGFP with GLAST, a specific SGC marker (Fig 2A; Table 2 ). In addition, 156 some cells expressing eGFP, and exhibiting a typical feature of non-myelinating Schwann cells, were 157 found in nerves attached to DRGs (Fig 2C; Table 2 ); this is expected for cells known to synthetize 158 S100β (34,35). However, 13.5% of sensory neuron soma (Fig 2B; Table 2 ) and their corresponding 159 axons (Fig 2C) were found to express eGFP. To test whether this unexpected neuronal eGFP 160 expression reflected normal endogenous S100β protein expression in DRGs of wildtype mice, we used 161 an antibody directed against S100β. S100β endogenous protein was detected in both DRG SGCs and 162 neurons of wildtype mice (S1 Fig), in agreement with the eGFP expression pattern observed in S100β-163 eGFP mice. Hence, the S100β promoter does not represent a valuable promoter to target transgene 164 expression selectively in DRG SGCs. However, it does allow eGFP expression in the vast majority of 165 DRG SGCs. 166 ALDH1L1-eGFP mice express eGFP in a subset of SGCs and some neurons. Another recently 167 discovered marker of astrocytes is the protein aldehyde dehydrogenase 1 family member L1 [aldh1l1; 168
(2)]. The ALDH1L1 promoter has been used to generate several transgenic mouse lines (2, 8, 36) , 169
including the ALDH1L1-eGFP mice that exhibit eGFP selectively in most astrocytes of the CNS (2). 170
In agreement, we found that eGFP is expressed in 82.1% of V1 astrocytes (Fig 3A; Table 2 ) with no 171 detectable expression in neurons (Fig 3B; Table 2 ). The distribution of eGFP-expressing cells was 172 then investigated in DRGs of ALDH1L1-eGFP mice. Enhanced GFP immunoreactivity was observed 173 only in 56.4% of SGCs (Fig 4A; Table 2) as well as in a low percentage (7.2%) of sensory neuron 174 soma, making this transgenic line unsuitable for the specific visualization of the majority of SGCs. 175 CX3CR1-eGFP mice show specific eGFP expression in macrophages. The CX3C chemokine receptor 176 1 (CX3CR1), known as the fractalkine receptor (3), is a marker of microglial cells (37,38). The 177 CX3CR1-eGFP mouse line, expressing eGFP under the control of the CX3CR1 promoter (3), has been 178 extremely useful to visualize microglial cells and dynamic changes in their morphology. In support of 179 this previous study, we found a selective eGFP expression in 99.5% of V1 microglial cells with no 180 detectable expression in neurons (Fig 5A,B ; Table 3 ). Since microglial cells are the CNS resident 181 macrophages, we reasoned that peripheral macrophages should also express eGFP in DRGs from 182 8 CX3CR1-GFP mice. Indeed, we observed that eGFP was expressed in 90.9% of Iba1-expressing 183 macrophages ( Fig 6A; Table 3 ), validating the use of the CX3CR1-eGFP mouse line for labeling a 184 prominent number of DRG macrophages and investigating their morphological remodeling. Note that 185 a few eGFP-positive elements did not express Iba1 (Fig 6A, arrow) . Because profiles are spotty and not found within the whole cytosol, but instead are localized in some 187 subcellular compartments of macrophages, such eGFP-positive elements might correspond to negative macrophage compartments. 189
190
MOUSE LINES FOR INVESTIGATING THE ROLES OF SGC Ca 2+ SIGNALING
191
GFAP-Cre::GCaMP6f mouse line expresses GCaMP6f Ca 2+ biosensor mainly in DRG sensory 192
neurons. Emerging evidence showing that Ca 2+ is an important signaling messenger in SGCs 193 (12, 39, 40) prompted us to search for molecular tools to probe SGC Ca 2+ dynamics. To do so, we took 194 advantage of the powerful CAG-lox-STOP-lox-GCaMP6f transgenic mouse line (7) that was recently 195 developed to express the genetically-encoded Ca 2+ indicator GCaMP6f in cell types of interest. We 196 first crossed CAG-lox-STOP-lox-GCaMP6f mice with GFAP-Cre mice (29) to generate Cre::GCaMP6f double transgenic mice. GFAP is indeed extensively used as a gold standard astrocytic 198 marker, which expression is enhanced in reactive astrocytes during aging, CNS injury, pain, and 199 diseases (41). GFAP has also been reported as a marker of DRG SGCs (11), although we have not 200 found convincing immunohistochemical evidence in the literature showing clear SGC GFAP 201 expression under physiological conditions. In agreement, in our hands, immunohistochemical 202 experiments conducted on DRGs from wildtype mice using two different antibodies directed against 203 GFAP ( Table 1) have revealed almost no GFAP-expressing SGCs (data not shown). However, a large 204 number of studies have shown increases in SGC GFAP expression level under pathological conditions, 205
including, peripheral nerve injury, DRG compression and pain (17, 24) . 206
In the CNS, GFAP is known to be expressed in neural progenitors during developmental stages, giving 207 rise to neurons, astrocytes and oligodendrocytes, thus preventing the use of the non-inducible GFAP-208
Cre mice and Cre-LoxP system to selectively study astrocytes (29, (42) (43) (44) . The observation that 209 astrocytes, neurons, and neuropil from V1 GFAP-Cre::GCaMP6f expressed GCaMP6f (Fig 7A,B) was 210 consistent with those previous studies and the view that recombination occurs during development. 211
However, because SGCs derive from the neural crest, a different lineage than astrocytic lineage, there 212 was a possibility that GFAP-Cre mice could be useful to drive gene expression selectively in a great 213 proportion of SGCs. In DRGs from GFAP-Cre::GCaMP6f mice, GCaMP6f was expressed in only 214 1.8% of SGCs while, to our surprise, it was observed in 58.5% of sensory neurons (including small-215 and large-sized diameter neurons; Fig 8A; Table 2 ). To assess whether GCaMP6f was expressed 216 under detectable levels in SGCs, SGC functional Ca 2+ signals were registered using 2-photon imaging 217 in intact ex vivo DRGs. Bath application of an agonist cocktail to G q GPCRs did not evoke any Ca 2+ 218 elevations in cells morphologically identified as SGCs (i.e. ring-shaped cells surrounding neuronal 219 soma). However, 23.5% of GCaMP6f-expressing sensory neurons exhibited marked intracellular Ca 2+ 220 elevations (Fig 8B) . Taken together these results show that the GFAP-Cre::GCaMP6f double 221 transgenic mouse line is not an adequate tool for studying Ca 2+ dynamics selectively in DRG SGCs. 222 GLAST-CreERT2::GCaMP6f and Cx30-CreERT2::GCaMP6f mice express GCaMP6f in a few or no 223 SGCs, respectively. GLAST has been conventionally used to identify a subset of astrocytes and the 224 majority of DRG SGCs (45-47), making the GLAST promoter a good candidate to target gene 225 expression in a large number of SGCs. Additionally, connexin 30 (Cx30) has also been used as a 226 marker of a fraction of astrocytes (45), although its expression in DRG SGCs has not yet been 227 reported. To determine whether GLAST and Cx30 promoters could drive GCaMP6f expression 228 selectively in SGCs, we crossed both inducible GLAST-CreERT2 (28) and Cx30-CreERT2 (28) mice 229 with CAG-lox-STOP-lox-GCaMP6f mice. To induce GCaMP6f expression in the resultant GLAST-230
CreERT2::GCaMP6f and Cx30-CreERT2::GCaMP6f double transgenic lines, mice were treated with 231 1 mg tamoxifen per day during 5 consecutive days. As expected, in the CNS (V1), GCaMP6f was 232 detected in 56.3% and 46.4% of astrocytes, in these two lines respectively (Fig 9A; Fig 10A; Table 2 ) 233
with an insignificant expression in neurons (0.03% and 0.1%, respectively; Fig 9B; Fig 10B; Table 2) . 234
In contrast, DRGs from GLAST-CreERT2::GCaMP6f mice showed GCaMP6f immunoreactivity in 235 only 5.4% of SGCs and a low percentage (3.8%) of sensory neurons (Fig 11A,B; Table 2) , 236 invalidating this mouse line for investigating Ca 2+ dynamics selectively in SGCs. Furthermore, no 237
GCaMP6f expression at all was found in SGCs or sensory neurons of Cx30-CreERT2::GCaMP6f (Fig  238   12A,B; Table 2 ), making this mouse line unsuitable to study Ca 2+ signaling in DRG SGCs. 239 Surprisingly though, GCaMP6f was observed in non-identified cells, which occasionally expressed 240 macrophage markers (Fig 12C) , suggesting that a few of them are macrophages. Of note, GCaMP6f 241 was also found to be expressed at the DRG surface, possibly in tissues encapsulating DRGs (Fig 12B) . 242
Cx43-CreERT2::GCaMP6f mouse line allows the detection of Ca 2+ transients in the vast majority of 243
SGCs. Cx43 is a widely used specific marker of a large proportion of CNS astrocytes and almost all 244 DRG SGCs (13,48), making it particularly relevant to astrocyte and SGC research. In another attempt 245 to establish a tool for monitoring Ca 2+ transients selectively in a great number of SGCs, we generated 246 the inducible Cx43-CreERT2::GCaMP6f double transgenic mouse line by crossing the tamoxifen-247 inducible Cx43-CreERT2 (30) with the CAG-lox-STOP-lox-GCaMP6f mice (7). Two weeks after 248 tamoxifen treatment, V1 cortex and DRGs were analyzed. To our disappointment, GCaMP6f 249 immunoreactivity was observed in only 9.5% of V1 astrocytes (Fig 13A; Table 2 ), a much lower 250 percentage than previously reported in hippocampal astrocytes (~70%; 31). Possible explanations for 251 these discrepancies are regional (V1 versus hippocampus) variability in transgene recombination 252 efficiency, in addition to the fact that we tested our mice 2 weeks after tamoxifen treatment compared 253 to 4 weeks (31). Furthermore, GCaMP6f was also detectable in a small subset (4.4%) of neurons ( Fig  254   13B; Table 2) . These results suggest that Cx43-CreERT2 mouse line may be ineffective for driving 255 substantial GCamP6f expression specifically in V1 astrocytes, even when treating mice 10 times (10 x 256 1 mg/kg tamoxifen) as previously reported (31). 257
However, and importantly, cellular immunohistochemical characterization in DRGs revealed that 258
GCaMP6f was expressed in 92.6% of SGCs and a very small subset (4%) of neurons (Fig 14A,B ; 259 Table 2 ). In conclusion, the inducible Cx43-CreERT2::GCaMP6f line can be used to study the role of 260 Ca 2+ activity in the majority of DRG SGCs. We believe that this mouse line will prove to be a valuable 261 tool to examine DRG SGC functions. 262
Discussion
263
In this study we report the characterization of several tools for investigating SGC and macrophage 264 morphological changes as well as Ca 2+ activity within DRGs. Our data show that most tested 265 transgenic mice widely used to investigate astrocyte morphology and function are not suitable for 266 studying DRG SGCs. Indeed, among these mice, some exhibit ectopic transgene expression in small to 267 large proportions of neurons while others show low to no transgene expression in SGCs. Among the other mouse lines we characterized, S100-eGFP line may be considered applicable to 280 some extent, even though eGFP was expressed in a substantial percentage of sensory neurons (13.5%), 281 but also in a great proportion of DRG SGCs (85.8%). The readily identifiable ring-shaped SGCs can 282 indeed be almost undoubtedly differentiated from the rounded neuronal cell bodies. Additionally, 283 eGFP expression was found to be brighter in SGCs relatively to neuronal cell bodies (Fig 2A,B) , 284 which helps ascertain the identity of both cell types. Of note, we found that eGFP expression in SGCs 285 and neurons reflects the endogenous S100 protein expression, showing that, in DRGs, S100 is not a 286 glial selective promoter. These data complement studies reporting that S100 promoter drives 287 transgene expression in some motor neurons within the brainstem and spinal cord (33, 51) .
12
The fact that the GFAP promoter drives merely no transgene expression in SGCs from GFAP-289
Cre::GCaMP6f mouse line is consistent with our immunohistochemistry data showing only rare 290 GFAP-expressing SGCs. Furthermore, our data showing Cre-mediated recombination in 58.5% of 291 sensory neurons in such GFAP-Cre::GCaMP6f mice suggest the possibility that GFAP is expressed in 292 DRG neuronal lineage during development. This possibility though is not supported by the absence of 293 evidence for a developmental GFAP expression in PNS neuronal lineage, while such expression is 294 well described in the CNS (52). Thus, together our results suggest that the GFAP promoter used in the 295 GFAP-Cre::GCaMP6f mice is not sufficient to drive a strong and selective expression of transgenes in 296 a large number of SGCs under physiological conditions. However, in disagreement of this hypothesis, 297 the same promoter (2.2kB human GFAP minimum promoter, 29) has been previously used 298 successfully to highly express a transgene selectively in the overwhelming majority of DRG SGCs 299 with no ectopic sensory neuronal expression (53). This implies that other factors (e.g. number of 300 transgene copies, gene microenvironment) may account for the variability of transgene expression 301 levels in SGCs and cell selectivity. Indeed, transgenes insert randomly into the genome and the 302 transgene expression cannot always mimic endogenous promoter activity. Thus, controlling gene 303 microenvironment represents a strategy to enhance the specificity of transgenic targeting. One 304 approach is to insert transgenes into a cassette containing all introns, promoter regulatory elements, 305 exons and 5' and 3' flanking DNA of the GFAP gene (52). This approach has been used in a recent 306 study showing specific transgene expression in SGCs of the trigeminal ganglia, although it remains to 307 be evaluated in DRG SGCs (49). Another approach is to insert transgenes into bacterial artificial 308 chromosomes (BACs) as they reduce the influence of chromosome position effects and allow more 309 predictable transgene expression patterns. Despite these advantages, BAC transgenic mice appear to 310 suffer from some remaining expression variation. Indeed, using the BAC-based GLAST-CreERT2 311 mice (28) to generate the GLAST-CreERT2::GCaMP6f mice, we obtained both (i) a marginal 312 percentage of GLAST-driven CreERT2-mediated recombination in DRG SGCs, and (ii) a lack of cell 313 specificity, while endogenous GLAST protein is selectively and prominently expressed in essentially 314 all SGCs (47). Therefore, it stands to reason that even though both, conventional and BAC-based 315 transgenesis, can lead to robust and cell specific transgene expression in the CNS glial cells, their 316 expression pattern may significantly differ in DRG glia (and vice versa). Knock-in technology may be 317 considered as a good alternative to traditional transgenic techniques; indeed it enables transgene 318 insertion at a specific glial gene locus of the mouse genome, which allows excellent control of gene 319 microenvironment, and thus is likely to better avoid chromosome position effects and circumvent the 320 above-discussed drawbacks associated with conventional and BAC-based transgenesis. Our findings 321 using the knock-in CX3CR1-eGFP mouse line does support the relevance of this approach by showing 322 specific eGFP expression in the vast majority of microglial cells and macrophages in V1 and DRGs, 323 respectively (Fig 5; Fig 6) . Thus, to improve DRG glial cell specific targeting, it would be of interest 324
in future studies to generate and/or use knock-in glial mouse models. One of such mouse models, the 325 knock-in GLAST-CreERT2 mouse line in which CreERT2 transgene is inserted at the GLAST gene 326 locus (54), appears to be a good candidate to examine next. 327
A large number of in vivo studies have used the GFAP or S100 promoters to drive different transgene 328 expression in astrocytes. Results from these studies are routinely interpreted as due to the expression 329 of transgenes only in astrocytes. Our finding that the GFAP or S100 promoters drive GCaMP6f or 330 eGFP expression in 58.8 % or 13.5% of DRG sensory neurons, respectively, should be considered 331 when interpreting in vivo results from such studies. 332
In conclusion, most of the tools tested in the current study were found ineffective in studying 333 selectively the majority of SGCs in DRGs, although a lot of molecular and functional similarities exist 334 between DRG SGCs and astrocytes. Therefore, further work is required for characterizing and 335 identifying other already available tools as well as developing new genetically-modified mouse lines 336 and adeno-associated viral tools to specifically target large proportions of DRG SGCs, but also 337 macrophages. Together with the two mouse lines validated here (Cx43-CreERT2::GCaMP6f and 338 CX3CR1-eGFP), these future molecular tools will be of prominent interest in understanding better 339 how DRG glia can modulate sensory information processing under physiological and pathological 340 conditions. 341 342 
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